完成临床学习和工作后，获McMaster大学免疫学博士学位，并在NIH做博士后研究。来到药物所后，担任课题组长，主要从事疫苗引起细胞免疫反应方面的研究，旨在阐明T细胞免疫的细胞与分子机制，特别是在粘膜表面对抗传染性和炎症以及癌症。另外在疾病模型中探索细胞重新编的治疗潜力，开展基础和应用研究，寻找更好的治疗方法。

主要研究方向包括免疫反应诱导与新型疫苗设计、疫苗与药物高效递送策略、细胞分化与效应分子机制、细胞再生潜能与组织损伤修复。利用多种细胞模型开展新药筛选，研究药物对干细胞及免疫细胞生物学特性、生存微环境、增值分化调控的影响，进一步探索疾病发展、细胞健康与异常、再生和组织修复等方面机制，寻求干细胞和疫苗干预技术在慢性疾病、自身免疫性疾病、组织损伤、退行性病变、传染病上的应用新途径。研究课题涉及细胞生物学、疫苗免疫学、药物传递系统、细胞激活与迁移、T记忆细胞、高效杀伤淋巴细胞以及新型疫苗载体和佐剂等。

1.Zhang L, Li M, Zhang G, Gao C, Wang S, Zhang T, Ma C, Wang L, Zhu Q*. Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine. Mol Pharm. 2021. 18(4):1573-1581.
2.Li JB, Li JJ, Li M, Gao C, Zhang L, Li M, Zhu Q*. Oral immunization induces a novel CXCR6(+) beta7(+) intraepithelial lymphocyte subset predominating in the small intestine. Scand J Immunol. 2021. 93(3):e12996.
3.Gao C, Zhuang X, Zhang L, Li M, Li JJ, Li JB, Zhu Q*. Fingolimod can act as a facilitator to establish the primary T-cell response with reduced need of adjuvants. Vaccine. 2018. 36(50):7632–7640.
4.Li MH, Xiao R, Li JB, Zhu Q*. Regenerative approaches for cartilage repair in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2017. 25(10):1577-1587.
5.Zhu Q*, Berzofsky JA. Oral vaccines: directed safe passage to the front line of defense. Gut Microbes. 2013. 4(3):246-252.
6.Zhu Q*, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Klinman DM, Sui Y, Gagnon S, Belyakov IM, Mumper RJ, Berzofsky JA. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med. 2012. 18(8):1291-1296
7.Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, Berzofsky JA. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest. 2010. 120(2):607-616.

1.一种口服小檗碱微囊纳米粒嵌合制剂及给药方案. 竺青, 张灵芝. 2017.11.2